ID   TIF1B_RAT               Reviewed;         835 AA.
AC   O08629; B2RYN5;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   20-JAN-2009, sequence version 2.
DT   02-OCT-2024, entry version 189.
DE   RecName: Full=Transcription intermediary factor 1-beta {ECO:0000305};
DE            Short=TIF1-beta;
DE   AltName: Full=E3 SUMO-protein ligase TRIM28;
DE            EC=2.3.2.27;
DE   AltName: Full=KRAB-associated protein 1;
DE   AltName: Full=Nuclear corepressor KAP-1;
DE   AltName: Full=RING-type E3 ubiquitin transferase TIF1-beta {ECO:0000305};
DE   AltName: Full=Tripartite motif-containing protein 28;
GN   Name=Trim28 {ECO:0000312|RGD:620289}; Synonyms=Kap1, Tif1b;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 197-281.
RA   Emison E.S., Lewis B.C., Shim H., Li Q., Dang C.V., Lee L.A.;
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   INTERACTION WITH ZNF382.
RX   PubMed=11154279; DOI=10.1128/mcb.21.3.928-939.2001;
RA   Gebelein B., Urrutia R.;
RT   "Sequence-specific transcriptional repression by KS1, a multiple-zinc-
RT   finger-Kruppel-associated box protein.";
RL   Mol. Cell. Biol. 21:928-939(2001).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24; SER-27; SER-474; SER-502;
RP   SER-684; SER-753 AND SER-758, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Nuclear corepressor for KRAB domain-containing zinc finger
CC       proteins (KRAB-ZFPs). Mediates gene silencing by recruiting CHD3, a
CC       subunit of the nucleosome remodeling and deacetylation (NuRD) complex,
CC       and SETDB1 (which specifically methylates histone H3 at 'Lys-9'
CC       (H3K9me)) to the promoter regions of KRAB target genes. Enhances
CC       transcriptional repression by coordinating the increase in H3K9me, the
CC       decrease in histone H3 'Lys-9 and 'Lys-14' acetylation (H3K9ac and
CC       H3K14ac, respectively) and the disposition of HP1 proteins to silence
CC       gene expression. Recruitment of SETDB1 induces heterochromatinization.
CC       May play a role as a coactivator for CEBPB and NR3C1 in the
CC       transcriptional activation of ORM1. Also a corepressor for ERBB4.
CC       Inhibits E2F1 activity by stimulating E2F1-HDAC1 complex formation and
CC       inhibiting E2F1 acetylation. May serve as a partial backup to prevent
CC       E2F1-mediated apoptosis in the absence of RB1. Important regulator of
CC       CDKN1A/p21(CIP1). Has E3 SUMO-protein ligase activity toward itself via
CC       its PHD-type zinc finger. Also specifically sumoylates IRF7, thereby
CC       inhibiting its transactivation activity. Ubiquitinates p53/TP53 leading
CC       to its proteasomal degradation; the function is enhanced by MAGEC2 and
CC       MAGEA2, and possibly MAGEA3 and MAGEA6. Mediates the nuclear
CC       localization of KOX1, ZNF268 and ZNF300 transcription factors. In
CC       association with isoform 2 of ZFP90, is required for the
CC       transcriptional repressor activity of FOXP3 and the suppressive
CC       function of regulatory T-cells (Treg). Probably forms a corepressor
CC       complex required for activated KRAS-mediated promoter hypermethylation
CC       and transcriptional silencing of tumor suppressor genes (TSGs) or other
CC       tumor-related genes in colorectal cancer (CRC) cells. Required to
CC       maintain a transcriptionally repressive state of genes in
CC       undifferentiated embryonic stem cells (ESCs). In ESCs, in collaboration
CC       with SETDB1, is also required for H3K9me3 and silencing of endogenous
CC       and introduced retroviruses in a DNA-methylation independent-pathway.
CC       Associates at promoter regions of tumor suppressor genes (TSGs) leading
CC       to their gene silencing. The SETDB1-TRIM28-ZNF274 complex may play a
CC       role in recruiting ATRX to the 3'-exons of zinc finger genes with
CC       atypical chromatin signatures to establish or maintain/protect H3K9me3
CC       at these transcriptionally active regions.
CC       {ECO:0000250|UniProtKB:Q13263, ECO:0000250|UniProtKB:Q62318}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27;
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Interacts with ZNF382 (PubMed:11154279). Interacts with SETX.
CC       Oligomer; the RBCC domain homotrimerizes and interacts with one
CC       molecule of KRAB to form the KRAB-KAP1 corepressor complex. Binding to
CC       a KRAB domain is an absolute requirement for silencing gene expression.
CC       Interacts with CEBPB and NR3C1. Interacts with a number of KRAB-ZFP
CC       proteins including ZNF10, ZFP53, ZFP68 and ZNF256. Interacts with
CC       NCOR1, NR3C1 and CHD3. Interacts with CEBPB (via the RING-type and PHD-
CC       type zinc fingers). Component of a ternary complex that includes
CC       TRIM28, a HP1 protein (CBX1, CBX3 OR CBX5), a KRAB domain-containing
CC       protein, and DNA. Interacts with CBX5 (via the PxVxL motif); the
CC       interaction occurs in interphase nuclei and competes for binding POGZ.
CC       Interacts with POGZ; the interaction competes for interaction with
CC       CBX5. Interacts with SETDB1; the interaction is enhanced by KAP1
CC       sumoylation, stimulates SETDB1 histone methyltransferase activity and
CC       gene silencing. Interacts (via the PHD-type zinc finger) with UBE2I;
CC       the interaction is required for sumoylation and repressor activity.
CC       Component of the TRIM28/KAP1-ERBB4-MDM2 complex involved in connecting
CC       growth factor and DNA damage responses. Interacts directly with ERBB4;
CC       the interaction represses ERBB4-mediated transcription activity.
CC       Interacts with MDM2; the interaction contributes to p53/TP53
CC       inactivation. Component of the TRIM28/KAP1-MDM2-p53/TP53; involved in
CC       regulating p53/TP53 stabilization and activity. Interacts (via the
CC       leucine zipper alpha helical coiled-coil) with E2F1 (central region);
CC       the interaction inhibits E2F1 acetylation and transcriptional activity.
CC       Interacts with PPP1CA; the interaction dephosphorylates TRIM28 at Ser-
CC       824 and forms a complex at the p21 promoter site. Interacts with
CC       PPP1CB; the interaction is weak but is increased on dephosphorylation
CC       at Ser-824. Interacts with SMARCAD1. Interacts with, and sumoylates
CC       IRF7. Interacts with MAGEC2. Part of a complex composed of TRIM28,
CC       HDAC1, HDAC2 and EHMT2. Interacts with AICDA. The large PER complex
CC       involved in the histone methylation is composed of at least PER2, CBX3,
CC       TRIM28, SUV39H1 and/or SUV39H2; CBX3 mediates the formation of the
CC       complex (By similarity). Interacts with NR4A3; the interactions
CC       potentiates NR4A3 activity on NurRE promoter (By similarity). Interacts
CC       (unphosphorylated or phosphorylated form) with ZBTB1 (via BTB domain)
CC       (By similarity). Probably part of a corepressor complex containing
CC       ZNF304, TRIM28, SETDB1 and DNMT1. Interacts with ATRX. Forms a complex
CC       with ATRX, SETDB1 and ZNF274 (By similarity). Interacts with ZFP568;
CC       the interaction mediates ZFP568 transcriptional repression activity (By
CC       similarity). Interacts with RRP1B (By similarity). Interacts with CRY1
CC       (By similarity). Interacts with ZNF263; recruited to the SIX3 promoter
CC       along with other proteins involved in chromatin modification and
CC       transcriptional corepression where it contributes to transcriptional
CC       repression (By similarity). Interacts with CYREN (via XLF motif) (By
CC       similarity). Interacts with TRIM17; this interaction prevents TRIM28
CC       activity (By similarity). Interacts with ZNF746 (By similarity).
CC       Interacts with PHF13 (By similarity). Interacts with ZNF354C (By
CC       similarity). Interacts with ZNF432; the interaction is independent of
CC       PARP1 (By similarity). {ECO:0000250|UniProtKB:Q13263,
CC       ECO:0000250|UniProtKB:Q62318, ECO:0000269|PubMed:11154279}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q62318}.
CC       Note=Associated with centromeric heterochromatin during cell
CC       differentiation through CBX1 (By similarity). Localizes to sites of DNA
CC       damage (By similarity). {ECO:0000250|UniProtKB:Q13263,
CC       ECO:0000250|UniProtKB:Q62318}.
CC   -!- DOMAIN: The HP1 box is both necessary and sufficient for HP1 binding.
CC       {ECO:0000250|UniProtKB:Q13263}.
CC   -!- DOMAIN: The PHD-type zinc finger enhances CEBPB transcriptional
CC       activity. The PHD-type zinc finger, the HP1 box and the bromo domain,
CC       function together to assemble the machinery required for repression of
CC       KRAB domain-containing proteins. Acts as an intramolecular SUMO E3
CC       ligase for autosumoylation of bromodomain.
CC       {ECO:0000250|UniProtKB:Q13263}.
CC   -!- DOMAIN: The RING-finger-B Box-coiled-coil/tripartite motif (RBCC/TRIM
CC       motif) is required for interaction with the KRAB domain of KRAB-zinc
CC       finger proteins. Binds four zinc ions per molecule. The RING finger and
CC       the N-terminal of the leucine zipper alpha helical coiled-coil region
CC       of RBCC are required for oligomerization.
CC       {ECO:0000250|UniProtKB:Q13263}.
CC   -!- DOMAIN: Contains one Pro-Xaa-Val-Xaa-Leu (PxVxL) motif, which is
CC       required for interaction with chromoshadow domains. This motif requires
CC       additional residues -7, -6, +4 and +5 of the central Val which contact
CC       the chromoshadow domain. {ECO:0000250|UniProtKB:Q13263}.
CC   -!- PTM: ATM-induced phosphorylation on Ser-825 represses sumoylation
CC       leading to the de-repression of expression of a subset of genes
CC       involved in cell cycle control and apoptosis in response to genotoxic
CC       stress. Dephosphorylation by the phosphatases, PPP1CA and PP1CB forms,
CC       allows sumoylation and expression of TRIM28 target genes.
CC       {ECO:0000250|UniProtKB:Q13263}.
CC   -!- PTM: Sumoylation/desumoylation events regulate TRIM28-mediated
CC       transcriptional repression. Sumoylation is required for interaction
CC       with CHD3 and SETDB1 and the corepressor activity. Represses and is
CC       repressed by Ser-824 phosphorylation. Enhances the TRIM28 corepressor
CC       activity, inhibiting transcriptional activity of a number of genes
CC       including GADD45A and CDKN1A/p21. Lys-555, Lys-780 and Lys-805 are the
CC       major sites of sumoylation. In response to Dox-induced DNA damage,
CC       enhanced phosphorylation on Ser-825 prevents sumoylation and allows de-
CC       repression of CDKN1A/p21. {ECO:0000250|UniProtKB:Q13263}.
CC   -!- PTM: Auto-ubiquitinated; enhanced by MAGEA2 and MAGEC2.
CC       {ECO:0000250|UniProtKB:Q13263}.
CC   -!- PTM: Citrullinated by PADI4. {ECO:0000250|UniProtKB:Q62318}.
CC   -!- PTM: ADP-ribosylated by SIRT6, promoting TRIM28/KAP1 interaction with
CC       CBX5, thereby contributing to the packaging of LINE-1 retrotransposon
CC       elements into transcriptionally repressive heterochromatin.
CC       {ECO:0000250|UniProtKB:Q62318}.
CC   -!- SIMILARITY: Belongs to the TRIM/RBCC family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC166843; AAI66843.1; -; mRNA.
DR   EMBL; U95041; AAB51518.1; -; mRNA.
DR   RefSeq; NP_446368.1; NM_053916.1.
DR   AlphaFoldDB; O08629; -.
DR   BMRB; O08629; -.
DR   SMR; O08629; -.
DR   BioGRID; 250580; 5.
DR   IntAct; O08629; 4.
DR   STRING; 10116.ENSRNOP00000031061; -.
DR   iPTMnet; O08629; -.
DR   PhosphoSitePlus; O08629; -.
DR   jPOST; O08629; -.
DR   PaxDb; 10116-ENSRNOP00000031061; -.
DR   Ensembl; ENSRNOT00000029996.3; ENSRNOP00000031061.2; ENSRNOG00000027487.3.
DR   Ensembl; ENSRNOT00055027966; ENSRNOP00055022487; ENSRNOG00055016489.
DR   Ensembl; ENSRNOT00060041547; ENSRNOP00060034428; ENSRNOG00060023972.
DR   Ensembl; ENSRNOT00065051941; ENSRNOP00065042755; ENSRNOG00065030085.
DR   GeneID; 116698; -.
DR   KEGG; rno:116698; -.
DR   UCSC; RGD:620289; rat.
DR   AGR; RGD:620289; -.
DR   CTD; 10155; -.
DR   RGD; 620289; Trim28.
DR   eggNOG; KOG2177; Eukaryota.
DR   GeneTree; ENSGT00940000160527; -.
DR   HOGENOM; CLU_005817_2_0_1; -.
DR   InParanoid; O08629; -.
DR   OMA; DCKDEVP; -.
DR   OrthoDB; 56754at2759; -.
DR   PhylomeDB; O08629; -.
DR   TreeFam; TF106455; -.
DR   Reactome; R-RNO-212436; Generic Transcription Pathway.
DR   Reactome; R-RNO-9843940; Regulation of endogenous retroelements by KRAB-ZFP proteins.
DR   UniPathway; UPA00886; -.
DR   PRO; PR:O08629; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000027487; Expressed in testis and 20 other cell types or tissues.
DR   GO; GO:0000785; C:chromatin; ISO:RGD.
DR   GO; GO:0000791; C:euchromatin; ISO:RGD.
DR   GO; GO:0000792; C:heterochromatin; ISO:RGD.
DR   GO; GO:0005654; C:nucleoplasm; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISS:BHF-UCL.
DR   GO; GO:0003682; F:chromatin binding; ISO:RGD.
DR   GO; GO:0070087; F:chromo shadow domain binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0035851; F:Krueppel-associated box domain binding; ISS:UniProtKB.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; ISS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0019789; F:SUMO transferase activity; ISO:RGD.
DR   GO; GO:0003713; F:transcription coactivator activity; ISS:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; ISO:RGD.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:RGD.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; ISO:RGD.
DR   GO; GO:0006325; P:chromatin organization; IBA:GO_Central.
DR   GO; GO:0060028; P:convergent extension involved in axis elongation; ISO:RGD.
DR   GO; GO:0006281; P:DNA repair; ISO:RGD.
DR   GO; GO:0007566; P:embryo implantation; ISO:RGD.
DR   GO; GO:0060669; P:embryonic placenta morphogenesis; ISO:RGD.
DR   GO; GO:0043045; P:epigenetic programming of gene expression; ISO:RGD.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:HGNC-UCL.
DR   GO; GO:0071514; P:genomic imprinting; ISO:RGD.
DR   GO; GO:0001701; P:in utero embryonic development; ISO:RGD.
DR   GO; GO:0045087; P:innate immune response; ISO:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0045869; P:negative regulation of single stranded viral RNA replication via double stranded DNA intermediate; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0090309; P:positive regulation of DNA methylation-dependent heterochromatin formation; ISS:UniProtKB.
DR   GO; GO:0045739; P:positive regulation of DNA repair; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:HGNC-UCL.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; ISS:UniProtKB.
DR   GO; GO:0016925; P:protein sumoylation; ISO:RGD.
DR   GO; GO:0044790; P:suppression of viral release by host; ISO:RGD.
DR   CDD; cd19846; Bbox1_TIF1b_C-VI; 1.
DR   CDD; cd19829; Bbox2_TIF1b_C-VI; 1.
DR   CDD; cd15623; PHD_TIF1beta; 1.
DR   CDD; cd16765; RING-HC_TIF1beta; 1.
DR   Gene3D; 1.20.920.10; Bromodomain-like; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 2.
DR   InterPro; IPR003649; Bbox_C.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR037373; KAP1.
DR   InterPro; IPR047059; TIF1b_Bbox1_Znf.
DR   InterPro; IPR047058; TIF1b_Bbox2_Znf.
DR   InterPro; IPR042713; TIF1beta_RING-HC.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR45915; TRANSCRIPTION INTERMEDIARY FACTOR; 1.
DR   PANTHER; PTHR45915:SF9; TRIPARTITE MOTIF CONTAINING 28; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF00643; zf-B_box; 2.
DR   Pfam; PF14634; zf-RING_5; 1.
DR   SMART; SM00502; BBC; 1.
DR   SMART; SM00336; BBOX; 2.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00184; RING; 2.
DR   SUPFAM; SSF57845; B-box zinc-binding domain; 1.
DR   SUPFAM; SSF57903; FYVE/PHD zinc finger; 1.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   PROSITE; PS50119; ZF_BBOX; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ADP-ribosylation; Bromodomain; Chromatin regulator;
KW   Citrullination; Coiled coil; Isopeptide bond; Metal-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..835
FT                   /note="Transcription intermediary factor 1-beta"
FT                   /id="PRO_0000056394"
FT   DOMAIN          698..802
FT                   /note="Bromo"
FT   ZN_FING         67..123
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         150..197
FT                   /note="B box-type 1; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         206..247
FT                   /note="B box-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         626..673
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   REGION          14..57
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          248..378
FT                   /note="Leucine zipper alpha helical coiled-coil region"
FT                   /evidence="ECO:0000250"
FT   REGION          249..378
FT                   /note="Interaction with MAGEC2"
FT                   /evidence="ECO:0000250"
FT   REGION          368..372
FT                   /note="Involved in binding PPP1CA"
FT                   /evidence="ECO:0000250"
FT   REGION          413..481
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          477..514
FT                   /note="HP1 box"
FT   MOTIF           482..495
FT                   /note="PxVxL motif"
FT   BINDING         155
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         158
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         179
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         183
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         211
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         214
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         234
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         239
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   MOD_RES         24
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         27
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         31
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         52
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         268
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62318"
FT   MOD_RES         306
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         342
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         379
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         419
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         439
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62318"
FT   MOD_RES         441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         471
FT                   /note="Citrulline"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         472
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         473
FT                   /note="Citrulline"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         474
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         480
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         490
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         499
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         502
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         595
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         684
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         690
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         698
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         753
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         756
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62318"
FT   MOD_RES         758
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         771
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         775
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         780
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q62318"
FT   MOD_RES         785
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   MOD_RES         825
FT                   /note="Phosphoserine; by ATM and ATR and dsDNA kinase"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        36
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        129
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        201
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        256
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        263
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        274
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        306
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        321
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        368
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        379
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        379
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        409
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        436
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        470
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        470
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        508
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        555
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        555
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        576
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        677
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        751
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        751
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        751
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        771
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        775
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        780
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        780
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CROSSLNK        805
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q13263"
FT   CONFLICT        220
FT                   /note="V -> A (in Ref. 2; AAB51518)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        263
FT                   /note="K -> R (in Ref. 2; AAB51518)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   835 AA;  88956 MW;  0E4245EA6CA45CA0 CRC64;
     MAASAAAATA AASAATAASA ASGSPGSGEG SAGGEKRPAA SSAAAASASA SSPAGGGGEA
     QELLEHCGVC RERLRPERDP RLLPCLHSAC SACLGPATPA AANNSGDGGS AGDGAMVDCP
     VCKQQCYSKD IVENYFMRDS GSKASSDSQD ANQCCTSCED NAPATSYCVE CSEPLCETCV
     EAHQRVKYTK DHTVRSTGPA KTRDGERTVY CNVHKHEPLV LFCESCDTLT CRDCQLNAHK
     DHQYQFLEDA VRNQRKLLAS LVKRLGDKHA TLQKNTKEVR SSIRQVSDVQ KRVQVDVKMA
     ILQIMKELNK RGRVLVNDAQ KVTEGQQERL ERQHWTMTKI QKHQEHILRF ASWALESDNN
     TALLLSKKLI YFQLHRALKM IVDPVEPHGE MKFQWDLNAW TKSAEAFGKI VAERPGTNST
     GPGPMAPPRA PGPLSKQGSG SSQPMEVQEG YGFGTDDPYS SAEPHVSGMK RSRSGEGEVS
     GLMRKVPRVS LERLDLDLTS DSQPPVFKVF PGSTTEDYNL IVIERGAAAA AAGQAGTVPP
     GAPGAPPLPG MAIVKEEETE AAIGAPPAAP EGPETKPVLM ALTEGPGAEG PRLASPSGST
     SSGLEVVAPE VTSAPVSGPG ILDDSATICR VCQKPGDLVM CNQCEFCFHL DCHLPSLQDV
     PGEEWSCSLC HVLPDLKEED GSLSLDGADS TGVVAKLSPA NQRKCERVLL ALFCHEPCRP
     LHQLATDSTF SMEQPGGTLD LTLIRARLQE KLSPPYSSPQ EFAQDVGRMF KQFNKLTEDK
     ADVQSIIGLQ RFFETRMNDA FGDTKFSAVL VEPPPLNLPS AGLSSQELSG PGDGP
//
